Nipah Virus Treatment Market

Nipah Virus Treatment Market: Introduction

Nipah virus (NiV) is an RNA virus that spreads via person-to-person contact. Fruit bats, also known as flying foxes, are the animal reservoir for NiV in nature. The virus was first discovered in 1999 in Malaysia and Singapore. The outbreak of NiV is common in countries such as Bangladesh and India. Infected fruit bats can spread the disease to people or other animals such as pigs, goats, horses, cats, and dogs. The symptoms of NiV are very severe and include headache, cough, fever, shortness of breath, and vomiting. The disease is fatal with a death rate ranging from 45% to 70%.

Nipah virus can be diagnosed by performing tests such as Real-time Polymerase Chain Reaction (RT-PCR) and Enzyme-linked Immune-sorbent Assay (ELISA). There is no specific treatment for the disease. Doctors generally use substitute vaccines or drugs for the treatment of NiV infection. Ribavirin was used to treat the infection during the first outbreak in Malaysia. Various studies have demonstrated that adding Remdesivir to Nipah treatment would help improve preparedness for future outbreaks.

Key Drivers and Opportunities in Global Nipah Virus Treatment Market

• Climate change has been conjectured as a major cause of various NiV outbreaks worldwide, including directly transmitted pathogens
• The July 2020 report of the United Nations identified seven trends driving increase in the emergence of zoonotic diseases, including rise in demand for animal protein; intensive and unsustainable farming practices; exploitation of wildlife; rapid urbanization; and the climate crisis
• Pharmaceutical companies are conducting clinical trials to develop robust NiV vaccines. In July 2022, Moderna, Inc. announced that the first participant has been dosed in a Phase 1 trial of its NiV vaccine candidate, mRNA-1215.
• In February 2022, Public Health Vaccines, LLC announced the beginning of its Phase 1 clinical trial to evaluate the immunogenicity and safety of the single-dose vaccine (PHV02) on NiV

North America to Dominate Global Nipah Virus Treatment Market

• North America is expected to hold the largest share of the global Nipah virus treatment market due to the R&D of new vaccines and drugs in the region. In March 2022, a team of researchers at the University of Texas developed a vaccine that could protect against the Nipah virus in just three days.

Pipeline Analysis of Global Nipah Virus Treatment Market

• In July 2022, The National Institute of Allergy and Infectious Diseases (NIAID) launched an early-stage clinical trial to assess the efficacy and the safety of an investigational vaccine to prevent infection with the Nipah virus
• In January 2022, Public Health Vaccine LLC initiated a Phase 1 randomized, single-center, double-blind, placebo-controlled, dose-response trial to evaluate the safety, tolerability, and immunogenicity of three dose levels of PHV02. The company has also announced plans to initiate Phase 2 trial in 2022 in a disease-endemic region.
• In April 2019, Jefferson Vaccine Center published their findings in the journal NPJ Vaccines regarding the development of a novel recombinant vaccine called NIPRAB that shows robust immunization against NiV in animal models

Key Players Operating in Global Nipah Virus Treatment Market

The global Nipah virus treatment market is consolidated, with a small number of large-scale vendors that control majority of the share. Market players are investing significantly in R&D activities to enhance their share. Key players operating in the global Nipah virus treatment are:

• Aurobindo
• Lupin Ltd.
• Minapharm
• Roche
• Siegfried
• Starlake Bioscience
• Vivacure
• Xaretto

Global Nipah Virus Treatment Market: Research Scope

Global Nipah Virus Treatment Market, by Drug Class

• Ribavirin
• Remedisivir
• Others

Global Nipah Virus Treatment Market, by Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Nipah Virus Treatment Market, by Region

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • France
  • U.K.
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
• Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa